Propylparaben

Propylparaben

SCHEMBL1078677

CCCOC(=O)c1ccc(O)cc1.O=C(O)c1ccc(O)cc1

nearest known ligand 0.86

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 4/20 0.86
ALDH1A1 P00352 3/20 0.86
TSHR P16473 2/20 0.86
CHRM1 P11229 1/20 0.86
SLC6A2 P23975 1/20 0.86
KDR P35968 1/20 0.86
TDP1 Q9NUW8 1/20 0.86
LMNA P02545 3/20 0.70
SMN1; SMN2 Q16637 3/20 0.70
MAPK1 P28482 2/20 0.70
CYP1A2 P05177 1/20 0.70
CYP2D6 P10635 1/20 0.70
CYP2C19 P33261 1/20 0.70
NR1H2 P55055 1/20 0.70
RNASEL Q05823 1/20 0.70
ESR2 Q92731 2/20 0.62
CA12 O43570 2/20 0.62
CA1 P00915 2/20 0.62
CA2 P00918 2/20 0.62
CA7 P43166 2/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Propylparaben SCHEMBL28614294 0.98 ESR1 (0.83) ESR1ALDH1A1TSHRCHRM1SLC6A2
Propylparaben SCHEMBL11484158 0.95 ALDH1A1 (0.78) ESR1ALDH1A1TSHRCHRM1SLC6A2
Propylparaben SCHEMBL977 0.93 ESR1 (1.00) ESR1ALDH1A1TSHRCHRM1SLC6A2
Propylparaben SCHEMBL429594 0.93 ESR1 (1.00) ESR1ALDH1A1TSHRCHRM1SLC6A2
SCHEMBL1995221 0.93 LMNA (0.75) ESR1ALDH1A1TSHRCHRM1SLC6A2
Terephthalic Acid SCHEMBL28622229 0.93 LMNA (0.75) ESR1ALDH1A1TSHRCHRM1SLC6A2
Propylparaben SCHEMBL6129826 0.91 ALDH1A1 (0.89) ESR1ALDH1A1TSHRCHRM1SLC6A2
Propylparaben SCHEMBL5671589 0.91 ESR1 (0.96) ESR1ALDH1A1TSHRCHRM1SLC6A2
Propylparaben SCHEMBL1010568 0.91 ESR1 (0.96) ESR1ALDH1A1TSHRCHRM1SLC6A2
Propylparaben SCHEMBL8779117 0.91 ESR1 (0.96) ESR1ALDH1A1TSHRCHRM1SLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275974-A1 Pharmaceutical Composition Of Piperazine Derivatives UCB, S.A. (BE) 2007-11-29 US claimed
EP-1768649-A2 PHARMACEUTICAL COMPOSITION OF PIPERAZINE DERIVATIVES UCB Farchim S.A. (CH) 2007-04-04 EP claimed
WO-2006005507-A2 PHARMACEUTICAL COMPOSITION OF PIPERAZINE DERIVATIVES UCB FARCHIM SA (CH) 2006-01-19 WO claimed
WO-2023069455-A1 MESEMBRINE DERIVATIVES KIRKLAND JUSTIN (US) 2023-04-27 WO disclosed
US-20220265552-A1 ESLICARBAZEPINE SUSPENSION Jubilant Generics Limited (IN) 2022-08-25 US disclosed
US-11318145-B2 Eslicarbazepine suspension Jubilant Generics Limited 2022-05-03 US disclosed
US-20210275539-A1 ESLICARBAZEPINE SUSPENSION Jubilant Generics Limited (IN) 2021-09-09 US disclosed
EP-3716944-A1 STABLE LIQUID COMPOSITION OF KETOPROFEN, SALTS AND ENANTIOMERS THEREOF Aziende Chimiche Riunite Angelini Francesco A.C.R. (IT) 2020-10-07 EP disclosed
US-20200281879-A1 STABLE LIQUID COMPOSITION OF KETOPROFEN, SALTS AND ENANTIOMERS THEREOF AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) 2020-09-10 US disclosed
EP-2349242-B1 AMINO ACID SALTS OF PROSTAGLANDINS NOVAER HOLDINGS INC (US) 2018-12-05 EP disclosed
EP-2906672-A1 SELF-THICKENING DETERGENTS Henkel AG&Co. KGAA (DE) 2015-08-19 EP disclosed
EP-1207854-A1 PRESERVED LIPOSOMES Arch Personal Care Products, L.P. (US) 2002-05-29 EP disclosed
WO-2001017507-A1 PRESERVED LIPOSOMES ARCH PERSONAL CARE PRODUCTS, L.P. (US) 2001-03-15 WO disclosed
US-6083854-A COMPRISING WIPE SUBSTRATE HAVING EMULSION COMPRISING WATER, SILICONE BASE, POLYMER, STABILIZER PHENOXYETHANOL; USED FOR SKIN CARE, MAKE-UP REMOVAL; BABY CARE PRODUCTS THE PROCTER & GAMBLE COMPANY (US) 2000-07-04 US disclosed
EP-0967968-A1 PHARMACEUTICAL OR COSMETIC COMPOSITION CONTAINING AT LEAST ONE RETINOID ROC (FR) 2000-01-05 EP disclosed
WO-1998038980-A1 PHARMACEUTICAL OR COSMETIC COMPOSITION CONTAINING AT LEAST ONE RETINOID ROC (FR) 1998-09-11 WO disclosed
US-5676934-A SUNSCREEN ACTIVE MATERIAL, BIOCIDE, ANTIOXIDANT, POLYVINYLPYRROLIDINE SUBSTANTIVE AID, EMOLLIENT, SOLVENT, ACRYLATE ENTRAPMENT POLYMER; DRY POWDER INTERNATIONAL CREATIONS, LTD. (US) 1997-10-14 US disclosed
US-4536399-A THICKENING AGENT, SODIUM LAURYL SUFLATE EMULSIFIER NORCLIFF THAYER, INC. (US) 1985-08-20 US disclosed
US-4400378-A THIAZOLO OR OXAZOLO COMPOUNDS KARL THOMAE GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 1983-08-23 US disclosed
US-3932622-A WATER-IN-OIL EMULSION, DISODIUM OR DIPOTASSIUM SALT OF N-ACETYLGLUTAMTIC ACID GENERAL FOODS CORPORATION (US) 1976-01-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275974-A1 Pharmaceutical Composition Of Piperazine Derivatives PAK5, P2RX5, IL5 ESR1 4197/4885ALDH1A1 171/4885TSHR 4472/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.